McKinsey Guru: 'A Lot of Heat on R&D'


March 10, 2003 | Philip Ma is a partner in the pharmaceutical, biotech, and medical devices practice at McKinsey & Co. A molecular biologist by training, Ma advises companies about their R&D strategy and productivity. He spoke with Bio·IT World's Mark D. Uehling.


Q: In reports and scholarly articles, you've suggested the cost of a new chemical entity could rise steeply. It's $800 million now. How high could it go?
A: When we did the work in concert with Lehman Brothers, I think it was $1.2 billion.


Q: Are clients concerned about that?
A: They're not comfortable at all. They are very concerned about the increasing cost. I think there is a lot of heat on R&D organizations.


Q: Will R&D dollars be spent outside large companies as a result?
A: That's happening already. There are lower cost areas for doing research. People are doing clinical trials in Eastern Europe, in Asia. They are working with companies in India, doing basic chemistry and bioinformatics.


Q: Has the pharmaceutical industry adopted some new technologies prematurely?
A: It was part of the excitement about the genomics industry — they were afraid of being left behind. Well, reality has set in. And, at least with the companies I talk to, they are being much more careful before they jump into [new technologies]. The result of which is, it is not a great environment to be developing tools. The customer has just gotten a lot more skeptical.


Q: Has technology made drug discovery messier?
A: When something is new, people are unclear about the best ways to use it. I wouldn't say technology has made things worse. It has made life more complicated. Any change in technology offers new opportunities, new pieces of information, which are always valuable.



Back to Technology Overload 




White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 
Apply at http://jobs.tessella.com   

oxford nanopore logo 


Early Access Collaborations ManagersClick here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Click to  Apply  

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .